Stock Events

Stock Events

SymBio Pharmaceuticals Limited 

$0.4655
16
+$0.19+65.95%Thursday 21:00

Statistics

Day High
0.3659
Day Low
0.3659
52W High
0.637
52W Low
0.2805
Volume
2,500
Avg. Volume
117
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Feb 11Expected
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
Next
-0.23
-0.18
-0.14
-0.09
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SYMQY. It's not an investment recommendation.
Apple
3
AAPL
Coca-Cola
3
KO
Mitsubishi UFJ Financial Group
3
8306.TSE
NTT
3
9432.TSE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca operates in similar therapeutic areas, including oncology, which is a key focus for SymBio.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb competes directly in the oncology and hematology space, areas of focus for SymBio.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a broad portfolio that includes oncology drugs, competing with SymBio's cancer-focused pipeline.
Merck
MRK
Mkt Cap368.89B
Merck is a leading company in oncology, directly competing with SymBio's cancer treatment developments.
Novartis
NVS
Mkt Cap303.67B
Novartis has a strong presence in oncology and hematology, competing with SymBio's product offerings.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences focuses on areas like oncology and hematology, overlapping with SymBio's interests.
Rogers
ROG
Mkt Cap2.37B
Roche, through its Genentech division, is a major player in oncology, posing competition to SymBio.
AMGEN
AMGN
Mkt Cap251.94B
Amgen's focus on innovative treatments in oncology and hematology makes it a competitor to SymBio.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical segment, competes in the oncology market, relevant to SymBio's focus.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie has a growing oncology portfolio, which puts it in direct competition with SymBio's therapeutic areas.

About

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
Show More
CEO
Fuminori Yoshida
Employees
91
Country
Japan
ISIN
US87150Y1001

Listings

TSE
JP
4582.TSE
OTC Link
US
SYMQY

0 Comments

Share your thoughts

FAQs

What is SymBio Pharmaceuticals Limited stock price today?▼
The current price of SYMQY is $0.47 USD — it has increased by +65.95% in the past 24 hours. Watch SymBio Pharmaceuticals Limited stock price performance more closely on the chart.
What is SymBio Pharmaceuticals Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange SymBio Pharmaceuticals Limited stocks are traded under the ticker SYMQY.
Is SymBio Pharmaceuticals Limited stock price growing?▼
SYMQY stock has risen by +65.95% compared to the previous week, the month change is a -16.56% fall, over the last year SymBio Pharmaceuticals Limited has showed a -26.92% decrease.
When is the next SymBio Pharmaceuticals Limited earnings date?▼
SymBio Pharmaceuticals Limited is going to release the next earnings report on February 11, 2027.
How many employees does SymBio Pharmaceuticals Limited have?▼
As of November 7, 2026, the company has 91 employees.
In which sector is SymBio Pharmaceuticals Limited located?▼
SymBio Pharmaceuticals Limited operates in the Health & Wellness sector.
When did SymBio Pharmaceuticals Limited complete a stock split?▼
The last stock split for SymBio Pharmaceuticals Limited was on June 26, 2019 with a ratio of 1:4.
Where is SymBio Pharmaceuticals Limited headquartered?▼
SymBio Pharmaceuticals Limited is headquartered in Tokyo, Japan.